GeneEdit AI
An AI-driven biotech using machine learning to predict and optimize CRISPR gene editing outcomes.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $125M
AI Company Overview
An AI-driven biotech using machine learning to predict and optimize CRISPR gene editing outcomes.
Genetic DiseasesOncology
Technology Platform
An AI/ML platform that models and predicts CRISPR gene editing outcomes to optimize guide RNA design and improve therapeutic safety and efficacy.
Funding History
1Total raised:$125M
PIPE$125M
Opportunities
Could become the essential predictive engine for the gene editing industry, de-risking clinical development across multiple disease areas.
Risk Factors
The AI models may not generalize well to complex in vivo human biology, and the field is rapidly evolving with new editors that may require new models.
Competitive Landscape
Competes with internal efforts at large gene editing companies and other AI-biotech startups, requiring superior predictive accuracy and validation.